CJC-1295: GHRH Analog Research Overview and Regulatory Context

CJC-1295 actually has human data. That alone puts it ahead of most peptides people inject. The data proves it raises growth hormone and IGF-1 for days. It proves nothing about whether that does anything useful. That gap, between the numbers moving and something actually improving, is the whole story. So let’s start there.

What CJC-1295 is — and which version we’re talking about

CJC-1295 is a synthetic copy of growth hormone-releasing hormone (GHRH), the hypothalamic signal that tells the anterior pituitary to release growth hormone. Native GHRH lasts only a few minutes in plasma because an enzyme, dipeptidyl peptidase IV (DPP-IV), chops it up fast. CJC-1295 was engineered to survive that.

Two versions get discussed, and the difference matters. CJC-1295 with DAC (Drug Affinity Complex) carries a maleimide group that bonds covalently to plasma albumin after injection, stretching the half-life to roughly 7–8 days and holding GH elevated. CJC-1295 without DAC, also called Modified GRF 1-29, is short-acting, with a half-life around 30 minutes and a more pulse-like GH release closer to how natural GHRH behaves.

Different half-lives, different GH profiles, different research uses. Popular discussion blurs the two into one thing. They aren’t.

What the published human data shows

CJC-1295 has published Phase II human data, which is rare in this space. A 2006 study in the Journal of Clinical Endocrinology and Metabolism by Teichman and colleagues tested CJC-1295 (with DAC) in healthy adults aged 21–61. Single doses raised mean plasma GH 2–10-fold above baseline for up to 6 days, with IGF-1 up 1.5–3-fold. Pharmacokinetics were linear and matched the albumin-binding mechanism. No serious adverse events. Injection site reactions were the most common finding. A follow-up study in the same journal by Ionescu and Frohman showed pulsatile GH release was preserved despite the sustained presence of CJC-1295 — pulse-pattern intact, not flattened.

That’s a more developed human dataset than almost any peptide here can claim. But read what it is: a pharmacokinetic and pharmacodynamic study, not an efficacy study. It shows the hormone curves move. Whether GH and IGF-1 swings of that size translate into more muscle, denser bone, faster recovery, or any clinical endpoint hasn’t been shown in controlled human trials.

Animal work in rodents looked at body composition and bone density, with results in line with what you’d expect from GH elevation. That doesn’t establish human relevance.

Where it sits with the FDA (and WADA)

The FDA hasn’t approved CJC-1295 for anything. It’s not on the 503A or 503B bulk substances lists, so compounding pharmacies have no clear legal route to prepare it in the US under current guidance.

CJC-1295 isn’t on the PCAC July 23–24, 2026 docket — but the reason isn’t that the regulators never looked. PCAC reviewed CJC-1295 at its December 4, 2024 meeting and voted against inclusion on the 503A bulk drug substances list. The FDA’s standard reasoning pattern applied: insufficient human safety data, mechanistic concerns about unintended endocrine effects, and lack of reproducible efficacy data outside small or open-label trials. Framing this as not-on-the-docket elides the docketed review that already happened, and the vote that went the way it went.

WADA’s 2026 Prohibited List S2 category — Growth Hormone Releasing Factors and their analogs — covers CJC-1295 whether the exact name is spelled out or not. If you compete, treat it as prohibited, in and out of competition.

The questions the studies didn’t answer

This is the honest part, so read it twice.

The efficacy question is wide open. Showing a compound raises GH and IGF-1 is not the same as showing it produces a meaningful outcome. The GH-axis is intricate, and pushing the hormones up from outside doesn’t reliably do what the body’s own GH pulses do.

Long-term human safety is not established. The Phase II study covered weeks. Months or years of use has no published clinical record. Sustained GH and IGF-1 elevation has open questions around insulin sensitivity and cell proliferation through IGF-1 pathways, and those need long-term human data to answer.

The with-DAC versus without-DAC distinction gets flattened constantly. Different half-lives, different release profiles, possibly different safety profiles. Treating them as interchangeable is a mistake people make routinely.

Where CJC-1295 lands

CJC-1295’s Phase II human pharmacokinetic data genuinely sets it apart. The GH and IGF-1 effects are documented in people, not just rats. The distance from measuring a hormone curve to showing a clinical benefit is still large, and it hasn’t been crossed.

The honest framing, if you’re tracking this: the human pharmacology is real and unusually well-documented, the efficacy column is empty, the long-term safety column is empty, and there’s no established compounding pathway in the US. The foundation is more developed than most. The clinical picture still isn’t.